* P3 Health Partners Inc is expected to show a rise in quarterly revenue when it reports results on November 12 for the period ending September 30 2024
* The Chicago Illinois-based company is expected to report a 26.4% increase in revenue to $364.449 million from $288.35 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
* LSEG's mean analyst estimate for P3 Health Partners Inc is for a loss of 4 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for P3 Health Partners Inc is $2.00, above its last closing price of $0.37.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.07 -0.05 -0.09 Missed -80
Mar. 31 2024 -0.11 -0.11 -0.16 Missed -50
Dec. 31 2023 -0.19 -0.11 -0.22 Missed -100
Sep. 30 2023 -0.29 -0.13 -0.12 Beat 45.5
Jun. -0.14 -0.13 -0.09 Beat 30.8
30 2023
Mar. 31 2023 -0.63 -0.67 -0.22 Beat 67.4
Dec. 31 2022 -0.91 -2.26 Missed -148.4
Sep. 30 2022 -0.47 -0.46 -0.27 Beat 41.7
This summary was machine generated November 8 at 22:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments